| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5029 | Tap1a-opt1 | Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy |
|
| DCC5030 | Tap1a-opt2 | Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy |
|
| DCC5031 | Tapi-2 Acetate | ADAM-17 (TACE) and MMP inhibitor, sensitizing cancer stem cells to the lethal effects of 5-FU and blocking shedding of TNF-α from cell membranes |
|
| DCC5032 | Tariquidar Dimesylate | Potent P-glycoprotein (P-gp) inhibitor |
|
| DCC5033 | Tas-303 Hydrochloride | Novel selective norepinephrine reuptake inhibitor, displaying significant norepinephrine transporter (NET) inhibitory activity toward the serotonin or dopamine transporters |
|
| DCC5034 | tasidotin Hydrochloride | Tubulin-binding dolastatin-15 analog, demostrating a wide spectrum of In Vivo antitumor activity |
|
| DCC5035 | Tasp0233278 | Potent and orally active V 1B receptor antagonist with antidepressant and anxiolytic activities in rodents |
|
| DCC5036 | Tasp0277308 | Potent and selective sphingosine 1-phosphate 1 (S1P1) receptor antagonist (IC50 = 7.8 nM) |
|
| DCC5037 | Tasp0412098 | Novel potent, selective, and orally active CRTH2 antagonist |
|
| DCC5038 | Tat Peptide (47-57) | Trans-activator of transcription (TAT) peptide, increasing Hepta-histidine (7H) permeability into cells for treatment of iPS cell-derived neurons carrying Tau or APP mutations suppressed Tau phosphorylation |
|
| DCC5039 | Tat-gap19 | Novel brain penetrant Cx43 hemichannel blocker |
|
| DCC5040 | Tavarua Deoxyriboside A | Potential neuroprotective agent, showing effects on cellular models of oxidative stress and neuroinflammation |
|
| DCC5041 | Tazanolast | Selective mast-cell-stabilizing agent, inhibiting ozone-induced airway hyperresponsiveness |
|
| DCC5042 | Tb-2-081 | Novel antagonist of IL-6 signaling |
|
| DCC5043 | Tbbl-0000316 | Novel antibiotic against Mycobacterium tuberculosis (Mtb), potently killing replicating, virulent Mtb H37Rv in a clavulanate-dependent manner |
|
| DCC5044 | Tbdps-chc | Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties |
|
| DCC5045 | Tbe-31 | Highly potent activator of Nrf2; Potent phase 2 cytoprotective pathway inducer and liver carcinogenesis blocker |
|
| DCC5046 | Tbk1 Inhibitor-1 | Novel TBK1/IKKε inhibitor |
|
| DCC5047 | Tbz-07 | Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity |
|
| DCC5048 | Tbz-19 | Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity |
|
| DCC5049 | Tc299423 | Novel agonist for nicotinic acetylcholine receptors (nAChRs), modestly selectively targeting α6β2 subtype |
|
| DCC5050 | Tc-ac28 | Novel potent and selective ligand of Brd2(2) |
|
| DCC5051 | Tc-aqp1-1 | Aquaporin 1 (AQP1) channel blocker |
|
| DCC5052 | tc-c-14g | Potent CB1 receptor inverse agonist |
|
| DCC5053 | Tc-e 5006 | Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels |
|
| DCC5054 | FPR Agonist 43 Featured | FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist. |
|
| DCC5055 | Tc-g1004 | Potent and selective antagonist of adenosine A2A receptors |
|
| DCC5056 | Tch-013 | Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines |
|
| DCC5057 | Tc-i 2000 Featured | Novel TRPM8 channel blocker |
|
| DCC5058 | Tc-i 2014 | Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models |
|
